Pharmacokinetics of a syrup formulation of amoxycillin-potassium clavulanate in children. 1986

U B Schaad, and P A Casey, and A T Ravenscroft

The pharmacokinetics of a syrup formulation consisting of four parts of amoxycillin and one part of potassium clavulanate (Augmentin) were studied in 11 paediatric patients, 3 to 14 years of age. Single oral doses of 25 mg of Augmentin per kg body weight (20 mg of amoxycillin per kg plus 5 mg of potassium clavulanate per kg, i.e. 1 mg of the syrup per kg) were administered on an empty stomach, and were well accepted and tolerated. Mean peak plasma concentrations 60-90 min after dosing were 7.2 mg/l for amoxycillin and 2.0 mg/l for clavulanic acid. Mean terminal phase plasma half-lives were 1.4 and 1.0 h, respectively. It is concluded that 25-mg/kg doses of this syrup formulation of Augmentin administered three times daily should be adequate therapy for various childhood bacterial infections.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002969 Clavulanic Acids Acids, salts, and derivatives of clavulanic acid (C8H9O5N). They consist of those beta-lactam compounds that differ from penicillin in having the sulfur of the thiazolidine ring replaced by an oxygen. They have limited antibacterial action, but block bacterial beta-lactamase irreversibly, so that similar antibiotics are not broken down by the bacterial enzymes and therefore can exert their antibacterial effects. Acids, Clavulanic
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

U B Schaad, and P A Casey, and A T Ravenscroft
February 1990, The Journal of antimicrobial chemotherapy,
U B Schaad, and P A Casey, and A T Ravenscroft
January 1997, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
U B Schaad, and P A Casey, and A T Ravenscroft
January 1997, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
U B Schaad, and P A Casey, and A T Ravenscroft
October 1994, Journal of clinical pharmacy and therapeutics,
U B Schaad, and P A Casey, and A T Ravenscroft
August 2007, The Japanese journal of antibiotics,
U B Schaad, and P A Casey, and A T Ravenscroft
January 1991, Acta oto-laryngologica,
U B Schaad, and P A Casey, and A T Ravenscroft
March 1988, Lancet (London, England),
U B Schaad, and P A Casey, and A T Ravenscroft
February 1988, Lancet (London, England),
U B Schaad, and P A Casey, and A T Ravenscroft
October 1982, Lancet (London, England),
U B Schaad, and P A Casey, and A T Ravenscroft
August 1982, Lancet (London, England),
Copied contents to your clipboard!